The gene signature for renal cancer can help clinicians identify recurrence risk earlier and potentially guide patient treatment strategies.
Vous n'êtes pas connecté
Researchers have identified a biomarker that can help determine which medlinkrenal cancer/medlink patients are at a higher risk of recurrence. The
The gene signature for renal cancer can help clinicians identify recurrence risk earlier and potentially guide patient treatment strategies.
Researchers at the University of Michigan Rogel Cancer Center have developed a 15-gene signature that helps classify clear cell kidney cancer patients...
Steatotic (fatty) liver disease is on the rise in many countries around the world. A rise in steatotic liver disease comes with an increase in the...
Researchers have identified a Vascular Endothelial Growth Factor Receptor (VEGFR) that could lead to new treatments for colon and renal cancers. ...
People with type 2 diabetes who are treated with GLP-1 agonists have a decreased risk of developing dementia, according to a new study from...
Treatment outcomes for breast cancer have become better over the years, but proportion of breast cancers still recur even after long periods without...
TUESDAY, June 25, 2024 -- Losing weight can protect you against cancers related to obesity, a new study finds. Obesity has been linked to higher risk...
Scientists have discovered novel immune responses that help explain how some individuals avoid getting COVID-19. Using single-cell sequencing,...
Researchers have identified potential mechanisms that allow long-lived mutants of the model organism Caenorhabditis elegans to preserve learning and...
Researchers from the Institut d’Investigació en Atenció Primària Jordi Gol (IDIAPJGol) and the Barcelona Institute for Global Health (ISGlobal),...